Biogen Inc (BIIB) - Return on Sales by Gross Profit

Official company branding of Biogen Inc (BIIB)

Risks of new drug failures and pricing pressure create uncertainty, necessitating stable plant operations under strict standards. This trend is captured by the gross margin indicator, where 64.00 serves as the final level marker. High scalability coupled with low vial production costs completes the picture, confirming the global sales potential of Biogen Inc. (BIIB).

BIIB: Biogen Gross Margin 07/04/2022 - 11/19/2026

Financial and market metric breakdowns for Biogen Inc. (BIIB)

- price and consensus price forecast:
- market capitalization indicators:
Basic company analysis:Biogen
Mass-produced product of Biogen Idec

Gross margin is calculated as the difference between total revenue and direct production costs. This indicator determines the efficiency of cost management and the company's ability to generate profit at a fundamental level. For Biogen Inc. (BIIB), high margins confirm the value of unique drugs within the established neurological disease therapy ecosystem. Analyzing the trend of the target gross margin allows for an assessment of the business model's resilience to market fluctuations.

Direct competitors

Gross Profit Margin Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Corp) - Gross Margin|AXSM: Gross Profit Rate|Gross Profitability acadia-pharm.com (ACAD)|Gross Margin Xenon Pharmaceuticals (XENE)|Gross Profitability Viking Therapeutics VKTX|Gross Profit Rate SUPN|CPRX - Gross Profitability|Gross Profit Margin Denali Therapeutics|HRMY: Gross Margin|Biohaven - Gross Profit Rate|Return on Gross Profit AMLX|Trevi Therapeutics, Inc. (TRVI) - Return on Sales by Gross Profit|Return on Gross Profit PRAX (Praxis Medicines)|Anavex Corp - Gross Return on Sales|Gross Profitability CeriBell CBLL|Return on Sales by Gross Profit Prothena Biosciences (PRTA)|ALEC: Return on Gross Profit|ANNX - Gross Margin|Omeros Corp. (OMER) - Gross Profitability|Gross Profit Margin Neurogene Inc. (NGNE)|Return on Gross Profit ACIU|Gross Profitability VYGR|Gross Profitability Neumora (NMRA)|SCLX - Gross Profit Margin|Gross Margin TVGN (Tevogen Bio Holdings Inc.)|Gross Profit Rate ACOG|Cognition Therapeutics Inc. - Gross Margin|IKT - Gross Margin|SAVA: Gross Margin|Assertio Holdings, Inc. - Gross Profit Rate|COYA (Coya) - Gross Margin|Gross Return on Sales VTGN (Vistagen Therapeutics)|Gross Profitability Ovid Rx (OVID)|Acumen Pharmaceuticals - Gross Return on Sales|Gross Profitability CervoMed, Inc. CRVO|Gross Margin Alterity Therapeutics ATHE|CLNN: Return on Gross Profit|PEPG (pepgen.com) - Gross Return on Sales|Jupiter Neurosciences Inc (JUNS) - Gross Profitability|Relmada Therapeutics - Gross Profit Rate|ANVS (Annovis Bio Inc) - Gross Margin|GRCE: Gross Profit Rate|Gross Profitability Firefly Neuroscience Inc (AIFF)|KLTO (ANEW Medical) - Gross Profit Rate|Gross Profitability neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Gross Profit Margin|MTVA: Return on Gross Profit|NeurAxis, Inc (NRXS) - Return on Gross Profit|HSDT: Gross Margin|PASG - Return on Sales by Gross Profit|Gross Profitability Neuphoria Therapeutics, Inc.|Gross Profitability NERV|Gross Margin ATHA|ADXN (Addex Therapeutics Ltd) - Gross Profit Rate|Gross Profitability alzamend.com ALZN|Return on Sales by Gross Profit Cyclerion Therapeutics (CYCN)|Protagenic - Gross Margin|Gross Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Gross Margin|Avenue Therapeutics Inc. (ATXI) - Gross Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Gross Margin|Gross Margin Cara Therapeutics Inc|Gross Profitability Chromocell Therapeutics (CHRO)|Gross Profit Ratio ELYM|Gross Profitability Intra-Cellular ITCI|LBPH: Gross Return on Sales|MRNS - Gross Profitability|NKGen Biotech, Inc. (NKGN) - Return on Gross Profit|neurobopharma.com (NRBO) - Gross Profitability|SAGE: Gross Profit Ratio|Gross Profitability Synaptogenix, Inc.|Gross Profitability TRVN|Gross Margin VIGL|Gross Margin anewmeds.com (WENA)|Gross Margin CERE (cerevel.com)